This Week
  • IV4 Inc. has managed to grow steadily over the years.

  • Michael Gioja is guiding information technology advances at Paychex Inc.

  • $6.8 million redevelopment project aims to help create unique neighborhood.

  • Shaina Sidoti's firm makes nutritious dishes that have helped her heal.

  • Changes to New York's estate tax have reduced the cost of dying here.

  • Area exporters starting 2014 with a sense of momentum.

Biotech firm Vaccinex begins clinical trial

Rochester Business Journal
January 7, 2013

Biotechnology firm Vaccinex Inc. has initiated a Phase I clinical trial to assess a therapeutic antibody candidate in patients with multiple sclerosis.

The trial will test the safety, tolerability and pharmacokinetics, or the analysis of the movement of drugs in the body. The antibody candidate, VX15/2503, targets the multi-functional protein semaphorin 4D and represents the second clinical trial for the investigational drug.

Studies have shown that anti-semaphorin 4D antibody can successfully ameliorate disease severity, officials said. Antibodies are proteins produced by the body as an immune response.

“It is particularly gratifying for Vaccinex to translate into the clinic the first therapeutic to target this important new class of regulatory molecules,” said Maurice Zauderer, president and CEO of Vaccinex, in a statement. “Research in our own and other laboratories has shown that the multiple activities of (semaphorin 4D) have a coordinated detrimental effect on progression of neurological diseases, several types of cancer and some other inflammatory and/or degenerative conditions.”

Vaccinex is completing a parallel trial of VX15/2503 antibody in patients with solid tumors, he said.

(c) 2013 Rochester Business Journal. To obtain permission to reprint this article, call 585-546-8303 or e-mail service@rbj.net.
 


What You're Saying 

There are no comments yet. Be the first to add yours!

Post Your Own Comment

 
Username:
Password:

Not registered? Sign up now!
 

To Do   Text Size
Post CommentPost A Comment eMail Size1
View CommentsView All Comments PrintPrint Size2
ReprintsReprints Size3
  • E-mailed
  • Commented
  • Viewed
RBJ   Google